"Investigators from the Women's Health Initiative (WHI) Hormone Trials are reaffirming conclusions that hormone therapy is not recommended for the prevention of chronic disease, but may remain a reasonable option for the short-term management "...
(Generic versions may still be available.)
- Clinician Information:
Cefotan Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Cefotan (cefotetan disodium for injection) is an antibiotic used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include swelling, redness, pain, or soreness at the injection site, loss of appetite, nausea, vomiting, diarrhea, or headache.
The usual adult dosage is 1 or 2 grams of Cefotan administered intravenously or intramuscularly every 12 hours for 5 to 10 days. Cefotan may interact with aminoglycosides. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Cefotan. This drug passes into breast milk in very low concentrations. Consult your doctor before breastfeeding.
Our Cefotan (cefotetan disodium for injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Cefotan FDA Prescribing Information: Side Effects
In clinical studies, the following adverse effects were considered related to CEFOTAN (cefotetan) therapy. Those appearing in italics have been reported during postmarketing experience.
Gastrointestinal: symptoms occurred in 1.5% of patients, the most frequent were diarrhea (1 in 80) and nausea (1 in 700); pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment or surgical prophylaxis. (See WARNINGS.)
Hematologic: laboratory abnormalities occurred in 1.4% of patients and included eosinophilia (1 in 200), positive direct Coombs' test (1 in 250), and thrombocytosis (1 in 300); agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, and prolonged prothrombin time with or without bleeding.
Local: effects were reported in less than 1% of patients and included phlebitis at the site of injection (1 in 300), and discomfort (1 in 500).
Urogenital: Nephrotoxicity has rarely been reported.
In addition to the adverse reactions listed above which have been observed in patients treated with cefotetan, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: pruritus, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, vomiting, abdominal pain, colitis, superinfection, vaginitis including vaginal candidiasis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, elevated bilirubin, pancytopenia, and neutropenia.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced. (See DOSAGE AND ADMINISTRATION and OVERDOSAGE.) If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Read the entire FDA prescribing information for Cefotan (Cefotetan) »
Additional Cefotan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.